Related Experiment Video
Updated: Jun 4, 2026
04:04
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Emerging therapeutics for primary peritoneal cancer
Brian M Slomovitz1, Michael J Worley, Maurie Markman
1Morristown Cancer Center, Division of Gynecologic Oncology, Morristown, NJ, USA.
Expert Opinion on Emerging Drugs
|March 1, 2011
Summary
Primary peritoneal cancer, similar to ovarian cancer, is being targeted by novel therapies. Angiogenesis inhibitors and targeted treatments show promise for both initial and recurrent disease management.
Area of Science:
- Gynecologic Oncology
- Medical Oncology
- Cancer Research
Background:
- Primary peritoneal cancer (PPC) originates from the abdominal lining, often involving the ovaries.
- PPC shares molecular and clinicopathologic features with primary ovarian cancer, leading to similar treatment approaches.
- Current treatment and drug development protocols largely consider PPC as a subtype of ovarian cancer.
Purpose of the Study:
- To review current drug development for primary peritoneal carcinoma.
- To highlight promising investigational agents in advanced clinical development.
- To discuss anticipated treatment changes due to recent bevacizumab data.
Main Methods:
- Medline search and review of National Cancer Institute clinical trials.
- Analysis of abstracts from major oncology congresses (SGO, ASCO).
- Focus on promising agents in mature clinical development and recent Phase III data.
Main Results:
- Numerous novel agents are under investigation for PPC.
- Most agents target tumor angiogenesis (blood vessel formation).
- Bevacizumab shows promise in first-line treatment settings.
Conclusions:
- Targeted therapies are expected to become standard for first-line and recurrent PPC.
- Future research will likely involve biomarker selection for pathway-specific targeting.
- Combinatorial treatment strategies are anticipated for enhanced efficacy.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...